Purpose of review
The purpose of the review is to summarize the current and future role of chemotherapy
in the treatment of patients with nonsmall cell lung cancer (NSCLC).
Recent findings Chemotherapy
has been established in early-stage, locally advanced and metastatic NSCLC. Patients with driver mutation-positive NSCLC receive tyrosine kinase inhibitors
as first-line therapy and chemotherapy
later during the course of their disease. Immune checkpoint inhibitors
have entered clinical practice as single agents or in combination with chemotherapy
. These novel treatments will supplement chemotherapy
in all tumor stages of NSCLC.
Targeted drugs and immune checkpoint inhibitors
are gaining increasing importance in the treatment of NSCLC. They will supplement but not replace chemotherapy
in the future.